ClinicalTrials.gg
Status unknownNCT05063253Updated Oct 1, 2021

A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes

A Phase 2 interventional study of TG103 and Placebo in Type 2 Diabetes Mellitus, sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Status unknown. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-10-01.

Sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Diabetes Mellitus, Type 2 by CSPC Pharmaceutical Group Limited — 1 open to participants now, 2 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · CSPC Pharmaceutical Group Limited.

Planned enrollment
12th of 16
208 · median 247
Started
2021
with 2 others
Phase 2
5 of 16
1 open now
Registered
9th of 16
by date

Among the 16 studies in Diabetes Mellitus, Type 2 by CSPC Pharmaceutical Group Limited, this one is the 12th largest by planned enrollment, is one of 3 that started in 2021, is one of 5 in phase 2, and was the 9th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 16 studies in Diabetes Mellitus, Type 2 by CSPC Pharmaceutical Group Limited is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Diabetes Mellitus, Type 2 by CSPC Pharmaceutical Group Limited, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy, safety, PK and PD characteristics of different doses of TG103 injection in overweight/obese subjects with type 2 diabetes mellitus.

Read the detailed description

This study is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of TG103 injection in subjects with type 2 diabetes mellitus combined with overweight/obesity. The study will consist of 3 periods: an approximately 4-week screening period, a 20-week treatment period, and a 3-week safety follow-up period. Eligible subjects will be randomized in a 1:1:1:1 ratio into four paralleled dose groups (15 mg, 22.5 mg ,30 mg and placebo) with 52 subjects in each group. Within each group, subjects will receive TG103 injection or placebo subcutaneously (SC) once a week (QW) over a period of 20 weeks. Each group will be started at a low dose of 7.5 mg and gradually up-titrated at weekly intervals until the target dose.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects have diagnosed with type 2 diabetes according to the Guidelines for prevention and treatment of type 2 diabetes in China (2020 Edition);
  2. Aged 18 to 75 years (inclusive), no gender limitation;
  3. (BMI) ≥ 24.0 kg/m\^2 with stable body weight (less than 5% self-reported change within 3 months);
  4. Subjects diagnosed with type 2 diabetes ≤ 3 years, and not on medication or with a history of regular medication for no more than 1 week within the 3 months prior to screening (subjects with a history of medication only include those with a history of single-agent oral medication and a history of short-term intensive insulin therapy (≤ 2 weeks)); 5.7.5% ≤ ≤ 10.0%;

6.Subjects of must use reliable methods of from the date of signing an to at least 3 months after the last dose; 7. The subject fully understand the trial and possible adverse reactions, has the ability to communicate properly with the investigator and comply with the research protocol; 8.Voluntarily participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Fasting plasma glucose ≥ 13.9 mmol/L at screening or a history of severe hypoglycemia (Serious event requiring help from others with changes in consciousness and/or body) within 6 months prior to screening;
  2. Systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥100 mmHg during screening;
  3. Have one or more positive tests in anti- antibody or anti-treponema pallidum-specific antibody;
  4. (AST) or Alanine aminotransferase (ALT) ≥2.5x (ULN), or Total (TBiL)≥1.5x ULN, or triglyceride > 5.7 mmol/L or \< 60 mL/(min*1.73 m\^2) during the screening period;
  5. Subjects with hematological diseases (e.g., aplastic anemia, myelodysplastic syndrome) or any disease causing hemolysis or erythrocyte instability (e.g., malaria), or \<100 g/L;
  6. Hypercortisolism, polycystic ovary syndrome, abnormal thyroid function (those requiring medication or who have not reached a stable dose of treatment in 3 months prior to screening), etc. or other diseases that may affect blood glucose metabolism;
  7. Have a personal or family history of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia, or other genetic diseases that are susceptible to medullary cancer, or calcitonin ≥ 50 ng/L(pg/mL);
  8. Acute complications of diabetes (including diabetic ketoacidosis, hyperosmolar nonketotic diabetic coma, lactic acidosis) occurred once or more within 3 months or twice or more within 6 months before screening;
  9. Proliferative diabetic retinopathy, foot ulcers/gangrene, and manifestations of peripheral neuropathy with obvious symptoms (e.g., gastroparesis, urinary retention, intestinal obstruction, urinary incontinence, and painful peripheral neuropathy);
  10. Subjects with degree II or III atrioventricular block in 12-lead (except for subjects who use the pacemaker), long syndrome or prolonged QTc interval (QTcF: >450 ms for males, >470 ms for females), or signs of localised ischemic heart disease during the screening period; or those with other heart diseases that are judged by the investigator to be unsuitable for entry into the study;
  11. Any of the following cardiovascular and cerebrovascular events within half a year before screening: unstable angina pectoris requiring hospitalization, myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention (diagnostic angiography is allowed), moderate to severe congestive heart failure ( grade III or IV), atrial or ventricular arrhythmia requiring hospitalization (such as atrial fibrillation and ventricular tachycardia), pacemaker or defibrillator implantation, or cerebrovascular accident (e.g. stroke), or those with coronary artery bypass grafting or revascularization planned during the study period;
  12. Have chronic or acute pancreatitis ( or have a history of recurrent acute pancreatitis), or serum amylase and/or lipase ≥ 3x ULN (If lipase cannot be detected in some centers, it is acceptable to judge only based on amylase),or severe gastrointestinal disease, such as confirmed reflux esophagitis or gallbladder disease, or any disease impacting gastric emptying (such as gastric bypass surgery, pyloric stenosis, except for appendectomy) or gastrointestinal diseases that may be aggravated by GLP-1 analogues; for subjects with a history of gallbladder stones (gallstone removal or lithotripsy) and/or cholecystectomy, access to the study will be determined by investigator after assessing the risk if there are no further sequelae;
  13. History of severe respiratory tract, blood system, central nervous system diseases (e.g., epilepsy, etc.), or history of malignant tumor (except for basal cell carcinoma or carcinoma in situ that has been clinically cured), mental diseases (e.g., depression, anxiety, etc.), or history of other diseases that may endanger the safety of the subjects and are considered unsuitable for this study in the investigator's opinion;
  14. Subjects who have undergone major surgery within 3 months before screening, or have ongoing severe or acute infection within 4 weeks before screening, or whose white blood cell count exceeds 10% of the upper limit of normal during the screening period;
  15. Use of drugs that can affect glucose metabolism or directly reduce gastrointestinal motility within the 3 months prior to screening or expected during the course of the study, including the cumulative use of systemic (topical, intraocular and inhaled preparations), and cytotoxic drugs for more than 7 days; Large doses of thiazide diuretics (hydrochlorothiazide>100 mg/d, chlorothiazide> 2 g/d, indapamide> 5 mg/d, chlorthalidone> 100 mg/d), anticholinergics, antispasmodics, etc. for more than 7 consecutive days;
  16. Have taken prescription or over-the-counter medications for weight loss (e.g., orlistat, sibutramine, rimonabant, phenylpropanolamine, or chlorphenimiindole, etc) within 3 months prior to screening; or have undergone surgery that can cause weight instability;
  17. Drugs that may cause significant weight gain have been used or are being used within 3 months before screening, including tricyclic antidepressants, atypical antipsychotics and mood stabilizers (e.g., midazolam, amitriptyline, mirtazapine, paroxetine, phenyl valproic acid and its derivatives and lithium), etc;
  18. Have a serious history of drug or food allergy, or may be allergic to the product according to the judgment of the investigator;
  19. Lost more than 400 mL of blood due to blood donation or other reasons within 3 months before the screening period;
  20. Average alcohol intake more than 21 units of alcohol (male)/14 units of alcohol (female) per week within the 3 months prior to screening;
  21. Regular consumption of caffeine more than 600 mg per day within the 3 months prior to screening;
  22. Smoke more than 20 cigarettes per day within 3 months prior to screening;
  23. Have skin abnormalities or dermatitis within a radius of 2 cm of the administration site;
  24. Participation in other drug studies within 3 months prior to screening and the last received test drug less than 3 months prior to screening; or subjects out of the group due to adverse events in the previous study; or attempted to participate in other drug trials during the study;
  25. Pregnant (blood pregnancy test positive in screening period) or lactating female;
  26. Vaccinated within 28 days before screening or planned to be vaccinated during the study;
  27. Not suitable for this study in the investigator's opinion.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
208 participants (estimated)

Study arms

  • Experimental
    TG103, 15 mg

    TG103 (15 mg) will be administered via subcutaneous injection once weekly.

    Drug: TG103

  • Experimental
    TG103, 22.5 mg

    TG103 (22.5 mg) will be administered via subcutaneous injection once weekly.

    Drug: TG103

  • Experimental
    TG103, 30 mg

    TG103 (30 mg) will be administered via subcutaneous injection once weekly.

    Drug: TG103

  • Placebo comparator
    Placebo

    Placebo will be administered via subcutaneous injection once weekly.

    Drug: Placebo

Interventions

  • DrugTG103

    TG103 injection, SC, once weekly

    Also known as: Administered SC

  • DrugPlacebo

    Placebo, SC, once weekly

    Also known as: Administered SC

06

What researchers measure

Primary outcomes

  1. Changes in glycosylated hemoglobin (HbA1c) from baseline to week 20

    Time frame: Baseline through Day 141 (the end of the 20-week treatment)

Secondary outcomes

  1. Change in body weight from baseline to week 20

    Time frame: Baseline through Day155 (the end of the follow-up)

  2. Change in body mass index (BMI) from baseline to week 20

    Time frame: Baseline through Day155 (the end of the follow-up)

  3. Change in waist circumference from baseline to week 20

    Time frame: Baseline through Day155 (the end of the follow-up)

  4. Change in waist-hip ratio from baseline to week 20

    Time frame: Baseline through Day155 (the end of the follow-up)

  5. Change in blood pressure(systolic and diastolic blood pressure) from baseline to week 20

    Time frame: Baseline through Day155 (the end of the follow-up)

  6. Change in blood lipid from baseline to week 20

    Time frame: Baseline through Day155 (the end of the follow-up)

  7. Proportion of subjects with a baseline weight loss of more than 5%

    Time frame: Baseline through Day155 (the end of the follow-up)

  8. Incidence of adverse events

    Time frame: Baseline through Day155 (the end of the follow-up)

  9. Minimum steady-state plasma drug concentration during a dosage interval (Cmin, SS)

    Time frame: Day1, 29, 57, 85 and 113

  10. Change in fasting blood glucose from baseline to week 20

    Time frame: Baseline through Day 141 (the end of the 20-week treatment)

  11. Change in 2-hour postprandial blood glucose from baseline to week 20

    Time frame: Baseline through Day 141 (the end of the 20-week treatment)

  12. The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (Nab).

    Time frame: Day1, 29, 57, 85, 113 and 155

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2021; primary completion for Mar 2024, 29 months later.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 29 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2021
First posted
Oct 1, 2021
StartEst.
Oct 2021
Primary completionEst.
Mar 2024
CompletionEst.
Mar 2024
Last update
Oct 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05063253
Responsible party
Sponsor
First posted
Oct 1, 2021
Start date
Oct 2021 (estimated)
Primary completion
Mar 2024 (estimated)
Completion
Mar 2024 (estimated)
Last update
Oct 1, 2021

Study contacts

Le Wang
Contact
wangle@mail.ecspc.com
+86-15511312686
Can Zhang
Contact
zhangcan@mail.ecspc.com
+86-18632118280
Dalong Zhu
principal investigator · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TG103

Start the discussion